SrasV1, 2020, Analysis, bibRecord, 000584

Human challenge studies to accelerate coronavirus vaccine licensure.

Identifieur interne : 000584 ( 2020/Analysis ); précédent : 000583; suivant : 000585

Human challenge studies to accelerate coronavirus vaccine licensure.

Auteurs : Nir Eyal [États-Unis] ; Marc Lipsitch [États-Unis] ; Peter G. Smith [Royaume-Uni]

Source :

The Journal of infectious diseases [ 1537-6613 ] ; 2020.

RBID : pubmed:32232474

Abstract

Controlled human challenge trials of SARS-CoV-2 vaccine candidates could accelerate the testing and potential rollout of efficacious vaccines. By replacing conventional Phase 3 testing of vaccine candidates, such trials may subtract many months from the licensure process, making efficacious vaccines available more quickly. Obviously, challenging volunteers with this live virus risks inducing severe disease and possibly even death. However, we argue that such studies, by accelerating vaccine evaluation, could reduce the global burden of coronavirus-related mortality and morbidity. Volunteers in such studies could autonomously authorize the risks to themselves, and their net risk could be acceptable if participants comprise healthy young adults, who are at relatively low risk of serious disease following natural infection, they have a high baseline risk of natural infection, and during the trial they receive frequent monitoring and, following any infection, the best available care.

DOI: 10.1093/infdis/jiaa152
PubMed: 32232474

Affiliations:

Links to Exploration step

pubmed:32232474

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Human challenge studies to accelerate coronavirus vaccine licensure.</title>
<author><name sortKey="Eyal, Nir" sort="Eyal, Nir" uniqKey="Eyal N" first="Nir" last="Eyal">Nir Eyal</name>
<affiliation wicri:level="4"><nlm:affiliation>Center for Population-Level Bioethics and Department of Philosophy, Rutgers University, New Brunswick, NJ, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Center for Population-Level Bioethics and Department of Philosophy, Rutgers University, New Brunswick, NJ</wicri:regionArea>
<placeName><region type="state">New Jersey</region>
<settlement type="city">New Brunswick (New Jersey)</settlement>
</placeName>
<orgName type="university">Université Rutgers</orgName>
</affiliation>
</author>
<author><name sortKey="Lipsitch, Marc" sort="Lipsitch, Marc" uniqKey="Lipsitch M" first="Marc" last="Lipsitch">Marc Lipsitch</name>
<affiliation wicri:level="2"><nlm:affiliation>Center for Communicable Disease Dynamics, Department of Epidemiology, and Departments of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, MA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Center for Communicable Disease Dynamics, Department of Epidemiology, and Departments of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, MA</wicri:regionArea>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Smith, Peter G" sort="Smith, Peter G" uniqKey="Smith P" first="Peter G" last="Smith">Peter G. Smith</name>
<affiliation wicri:level="3"><nlm:affiliation>Tropical Epidemiology Group, London School of Hygiene & Tropical Medicine, London, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Tropical Epidemiology Group, London School of Hygiene & Tropical Medicine, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32232474</idno>
<idno type="pmid">32232474</idno>
<idno type="doi">10.1093/infdis/jiaa152</idno>
<idno type="wicri:Area/PubMed/Corpus">000432</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000432</idno>
<idno type="wicri:Area/PubMed/Curation">000432</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000432</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000465</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000465</idno>
<idno type="wicri:Area/Ncbi/Merge">003659</idno>
<idno type="wicri:Area/Ncbi/Curation">003659</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">003659</idno>
<idno type="wicri:Area/Main/Merge">000584</idno>
<idno type="wicri:Area/Main/Curation">000584</idno>
<idno type="wicri:Area/Main/Exploration">000584</idno>
<idno type="wicri:Area/2020/Extraction">000584</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Human challenge studies to accelerate coronavirus vaccine licensure.</title>
<author><name sortKey="Eyal, Nir" sort="Eyal, Nir" uniqKey="Eyal N" first="Nir" last="Eyal">Nir Eyal</name>
<affiliation wicri:level="4"><nlm:affiliation>Center for Population-Level Bioethics and Department of Philosophy, Rutgers University, New Brunswick, NJ, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Center for Population-Level Bioethics and Department of Philosophy, Rutgers University, New Brunswick, NJ</wicri:regionArea>
<placeName><region type="state">New Jersey</region>
<settlement type="city">New Brunswick (New Jersey)</settlement>
</placeName>
<orgName type="university">Université Rutgers</orgName>
</affiliation>
</author>
<author><name sortKey="Lipsitch, Marc" sort="Lipsitch, Marc" uniqKey="Lipsitch M" first="Marc" last="Lipsitch">Marc Lipsitch</name>
<affiliation wicri:level="2"><nlm:affiliation>Center for Communicable Disease Dynamics, Department of Epidemiology, and Departments of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, MA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Center for Communicable Disease Dynamics, Department of Epidemiology, and Departments of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, MA</wicri:regionArea>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Smith, Peter G" sort="Smith, Peter G" uniqKey="Smith P" first="Peter G" last="Smith">Peter G. Smith</name>
<affiliation wicri:level="3"><nlm:affiliation>Tropical Epidemiology Group, London School of Hygiene & Tropical Medicine, London, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Tropical Epidemiology Group, London School of Hygiene & Tropical Medicine, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">The Journal of infectious diseases</title>
<idno type="eISSN">1537-6613</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Controlled human challenge trials of SARS-CoV-2 vaccine candidates could accelerate the testing and potential rollout of efficacious vaccines. By replacing conventional Phase 3 testing of vaccine candidates, such trials may subtract many months from the licensure process, making efficacious vaccines available more quickly. Obviously, challenging volunteers with this live virus risks inducing severe disease and possibly even death. However, we argue that such studies, by accelerating vaccine evaluation, could reduce the global burden of coronavirus-related mortality and morbidity. Volunteers in such studies could autonomously authorize the risks to themselves, and their net risk could be acceptable if participants comprise healthy young adults, who are at relatively low risk of serious disease following natural infection, they have a high baseline risk of natural infection, and during the trial they receive frequent monitoring and, following any infection, the best available care.</div>
</front>
</TEI>
<affiliations><list><country><li>Royaume-Uni</li>
<li>États-Unis</li>
</country>
<region><li>Angleterre</li>
<li>Grand Londres</li>
<li>Massachusetts</li>
<li>New Jersey</li>
</region>
<settlement><li>Londres</li>
<li>New Brunswick (New Jersey)</li>
</settlement>
<orgName><li>Université Rutgers</li>
</orgName>
</list>
<tree><country name="États-Unis"><region name="New Jersey"><name sortKey="Eyal, Nir" sort="Eyal, Nir" uniqKey="Eyal N" first="Nir" last="Eyal">Nir Eyal</name>
</region>
<name sortKey="Lipsitch, Marc" sort="Lipsitch, Marc" uniqKey="Lipsitch M" first="Marc" last="Lipsitch">Marc Lipsitch</name>
</country>
<country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Smith, Peter G" sort="Smith, Peter G" uniqKey="Smith P" first="Peter G" last="Smith">Peter G. Smith</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/2020/Analysis

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000584 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/2020/Analysis/biblio.hfd -nk 000584 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    2020
   |étape=   Analysis
   |type=    RBID
   |clé=     pubmed:32232474
   |texte=   Human challenge studies to accelerate coronavirus vaccine licensure.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/2020/Analysis/RBID.i   -Sk "pubmed:32232474" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/2020/Analysis/biblio.hfd   \
       | NlmPubMed2Wicri -a SrasV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

Serveur d'exploration SRAS

Human challenge studies to accelerate coronavirus vaccine licensure.

Human challenge studies to accelerate coronavirus vaccine licensure.

Source :

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.